The China Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The global prevalence rate of CIDP ranges between 1.6 and 7/100,000 population and may vary based on the diagnostic criteria used. Globally the prevalence of CIDP increases with age, and in patients over 65 years of age, the prevalence increases by 1.5 times. The condition was 1.4 to 4.7 times more common in men than women.
The market is majorly driven by the rising burden of autoimmune diseases in China. The Chronic Inflammatory Demyelinating Polyneuritis drug market in China is growing due to growth in the medical research sector, increase in air pollution (AQI of China 98). Apart from these the other factors also contributing for market growth such as increase in global prevalence rate (1.6 to 7 per 1,00,000), increase in age (average onset age is 48 to 58 years).
There are some restraining factors for growth of Chronic Inflammatory Demyelinating Polyneuritis therapeutics market in China such as underdiagnosis of disease and lack of awareness.